ClinicalTrials.gg
RecruitingNCT07453927CGU01_BLUpdated Apr 6, 2026

Blue Light for Donor Site Healing in Burn Patients

An interventional study of Photobiomodulation with blue light in Donor Site Complication, Burn and Photobiomodulation Therapy, sponsored by AUSL Romagna Rimini. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by AUSL Romagna Rimini · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Sep 2025, registered Mar 2026).
  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Burns with a site in Italy — 3 open to participants now, 6 under way, 1 of them phase 3. Burns · Italy.

Planned enrollment
8th of 14
25 · median 48
Started
2025
with 1 other
No phase
5 of 18
1 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
AUSL Romagna Rimini

Among the 18 studies in Burns with a site in Italy, this one is the 8th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 with no phase, and was the 18th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

3 of the 18 studies in Burns with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Burns with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether blue light (BL) photobiomodulation can improve the healing of donor site (DS) wounds in patients with burn injuries who are treated surgically. This study will investigate whether adding BL therapy to the usual treatment can improve healing and patient outcomes in adult patients with intermediate and deep burns.

The main questions it aims to answer are:

  • Does the use of BL therapy combined with standard treatment reduce the healing time of DS compared with standard treatment alone?
  • Does BL therapy improve wound conditions, reduce pain, and decrease signs of infection during the healing process?
  • Is BL therapy safe and well tolerated when applied to DS?
  • Does the treatment improve the long-term quality of the scar after healing?

Researchers will compare DS areas treated with standard care alone to DS areas treated with standard care plus BL therapy to see whether BL improves healing outcomes. Each participant will serve as their own comparison: two different DS areas on the same patient will receive the two different treatments.

Participants will:

  • Receive the standard treatment for DS, which includes routine wound care and dressing
  • Receive BL therapy on one DS area in addition to the standard treatment, while another DS area will receive standard treatment alone
  • Attend regular clinical evaluations where clinicians will assess wound healing and the condition of the wound bed
  • Report their pain levels using a simple numeric scale during the healing period
  • Undergo skin swabs to detect possible signs of infection
  • Be monitored for any local side effects, such as redness, burning sensation, warmth, itching, or skin irritation related to the light treatment

After the DS have completely healed, participants will return for follow-up visits at 1 month and 3 months. During these visits, researchers will evaluate the quality of the scars and monitor for any late side effects.

Read the detailed description

Burn injuries frequently require surgical treatment with split-thickness skin grafting. This procedure involves harvesting skin from a healthy area of the body, commonly referred to as the donor site (DS). Although donor sites are considered superficial wounds, their healing process can be associated with clinically relevant complications, including delayed re-epithelialization, pain, inflammation, and risk of infection. These complications may prolong hospitalization, negatively affect patient comfort and quality of life, and influence the overall outcome of burn management. Therefore, strategies that may accelerate DS healing while maintaining safety and tolerability are of considerable clinical interest.

Photobiomodulation with blue light (BL) has emerged as a promising therapeutic approach in the management of several types of skin wounds. Experimental and clinical evidence suggests that BL may exert antimicrobial effects, modulate inflammatory processes, and stimulate tissue repair mechanisms involved in wound healing. These biological effects could potentially support faster re-epithelialization and improved wound bed conditions. However, clinical evidence specifically addressing the role of BL therapy in DS healing among burn patients remains limited.

This clinical investigation aims to evaluate the clinical effectiveness and safety of BL photobiomodulation when used in addition to the Standard of Care (SoC) for the treatment of DS wounds in patients undergoing skin grafting for burn injuries.

Study Design The study is designed as an interventional, controlled, prospective, single-center post-market clinical study. The intervention involves the use of a CE-marked medical device (EmoLED) that emits blue light and is already approved and routinely used in clinical practice in accordance with the manufacturer's indications and applicable regulatory standards.

The study will enroll 25 patients with intermediate or deep burn injuries who require surgical treatment with split-thickness skin grafting and who present at least two DS areas suitable for comparative evaluation.

To reduce inter-individual variability and improve the internal validity of the study, an intra-patient controlled design will be used. Each participant will serve as their own control. Two donor site areas will be assigned to different treatment modalities:

  • Experimental treatment: SoC plus BL therapy
  • Control treatment: SoC alone In the study protocol, the DS on the right will receive the experimental treatment (SoC + BL), while the DS on the left will receive the SoC only. This design allows a direct comparison of clinical outcomes between the two treatment strategies within the same patient, minimizing the influence of patient-specific variables such as age, comorbidities, systemic inflammatory response, and nutritional status.

Study Procedures The day of the surgical intervention will be considered Day 0, during which the Case Report Form (CRF) will be prepared and baseline patient data will be collected. The DS areas will be measured and documented, including photographic documentation.

The experimental treatment with BL will begin at the first postoperative dressing change (Day 2) and will be repeated once per week for a total treatment duration of approximately 3-4 weeks, depending on the healing progression. BL will be applied to the entire donor site area for 60 seconds during each session using the study device.

DS assigned to the control arm will receive only the SoC, according to the wound care procedures routinely applied at the study center.

Clinical evaluation of both DS will be performed weekly during the treatment period, including completion of the CRF and collection of relevant clinical data. Each evaluation will include:

  • direct clinical observation of the wound
  • completion of validated clinical assessment scales
  • structured patient interview when feasible
  • laboratory reporting of skin swab results when performed
  • standardized photographic documentation of donor site areas The treatment phase is expected to last approximately 30 days, or until complete re-epithelialization of the DS. After wound healing, participants will undergo follow-up visits at 1 month and 3 months to evaluate the quality of the resulting scars and monitor potential late adverse events. When patients are discharged from the hospital before completion of follow-up, these assessments will be performed at the dedicated outpatient clinic of the study unit.

Data Sources and Data Collection

Data collected during the study will originate from source documents, including:

  • hospital medical records
  • clinical assessment scales
  • photographic documentation
  • laboratory reports (skin swab analysis)
  • paper or electronic Case Report Forms (CRFs) Data will initially be recorded in paper CRFs and subsequently entered into an electronic database for analysis. Immediate completion of the CRF at the end of each visit will be encouraged to reduce missing or incomplete data.

Data Quality Assurance

Several procedures will be implemented to ensure data validity, accuracy, and completeness, including:

  • cross-checking between medical records and CRFs to verify data consistency
  • double data entry when digital transcription is performed, in order to minimize transcription errors
  • standardized training of all members of the research team on study procedures and data collection methods
  • periodic monitoring of CRFs by the study monitor to verify completeness and data quality
  • systematic archiving of clinical photographs identified by patient code To ensure the reliability of visual assessments, photographic documentation will be reviewed by at least two trained clinical operators, who will independently evaluate wound characteristics and healing progression.

Safety Monitoring Safety assessments will be conducted throughout the study in accordance with standard clinical practice and the study protocol.

The following safety parameters will be monitored:

  • occurrence of adverse events (AE) potentially related to blue light exposure
  • occurrence of serious adverse events (SAE) during the treatment and follow-up periods

Potential local adverse reactions to BL therapy may include:

  • sensation of warmth or heat
  • skin irritation
  • erythema
  • itching or rash

All AE and SAE will be documented in the CRF, including:

  • date of onset and resolution
  • severity
  • suspected relationship to the treatment
  • clinical outcome AE will be collected at each dressing change and at any additional time when the patient reports symptoms or complications. Serious adverse events will be reported within 24 hours from the time they become known to the investigator, in accordance with applicable regulatory requirements.

Based on currently available evidence and the safety profile of the device, no specific risks related to study participation are anticipated beyond those associated with standard wound care procedures.

Protocol Deviations All protocol deviations will be identified, documented, and managed in compliance with Good Clinical Practice (GCP) and applicable regulatory requirements.

Potential deviations may include:

  • Incorrect allocation of DS areas (experimental vs control). An inadvertent inversion between treated and control areas could occur. In such cases, the deviation will be documented and the analysis will be corrected according to the actual treatment administered. To prevent this error, DS will be clearly labeled and photographed at the time of the first treatment.
  • Missed or delayed follow-up visits. Some participants may not attend the scheduled follow-up visits at 1 or 3 months. In these cases, attempts will be made to reschedule the visit whenever possible. Reminder phone calls and scheduling flexibility will be implemented to improve adherence. If follow-up data cannot be recovered, the missing information will be handled as missing data during statistical analysis.
  • Missed application of blue light therapy. If the experimental treatment is not applied during a scheduled dressing change due to logistical or operational issues, the treatment will be administered at the next dressing session without excluding the wound pair from the main statistical comparison. Procedural checklists and regular team briefings will be used to minimize the risk of recurrence.

Statistical Analysis Plan Baseline demographic and clinical characteristics of enrolled patients will be summarized using descriptive statistics.

Because each patient contributes two DS, the statistical unit of analysis will be the individual wound, with paired observations within the same patient.

Comparisons between treatment modalities will be performed using paired statistical tests, selected according to the distribution and type of variables:

  • parametric tests for normally distributed continuous variables
  • non-parametric paired tests for non-normal distributions
  • categorical data analysis where appropriate

The time to complete wound healing will be analyzed using survival analysis techniques, including:

  • Kaplan-Meier survival curves
  • log-rank test for comparison between treatment conditions Results will be reported using point estimates and 95% confidence intervals. The level of statistical significance will be set at p \< 0.05. The planned sample size of 25 participants is considered adequate for this exploratory clinical investigation and allows paired comparisons of DS within subjects while ensuring feasibility within a single specialized burn center.

Handling of Missing Data Missing data may arise from incomplete assessments, missed follow-up visits, or documentation errors. When missing data occur, the circumstances will be documented in the CRF. Whenever possible, attempts will be made to retrieve missing information through review of medical records or contact with the patient.

Data that remain unavailable will be treated as missing values in the statistical analysis, and sensitivity analyses may be performed when appropriate to evaluate their potential impact on study results.

03

Conditions studied

  • Donor Site Complication
  • Burn
  • Photobiomodulation Therapy
  • Blue Light

Browse trials for

Keywords

  • donor site
  • burns
  • photobiomodulation
  • blue light
  • healing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with intermediate-deep burns with Total Body Surface Area (TBSA) > 10% requiring surgical treatment with escharectomy, presenting at least two Donor Site.
  • Patients over 18 years of age;
  • Patients who have signed the Form (ICF) and understood the purpose of the study, or, if unable to give consent personally due to their condition, their legal guardian.

Exclusion criteria

Exclusion Criteria:

  • Intermediate-deep burns TBSA \< 10% or superficial burns;
  • Patients under the age of 18;
  • Patients who are participating in other clinical trials with drugs or medical devices;
  • Patients with neoplasms or other conditions requiring the use of cytostatic or drugs;
  • Patients with conditions that induce skin photosensitivity;
  • Pregnant or breastfeeding women;
  • Patients or relatives who are unable to understand the purposes of the trial;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Experimental treatment

    Standard treatment + Blue Light

    Device: Photobiomodulation with blue light

  • No intervention
    Standard Treatment

    Standard Treatment

Interventions

  • DevicePhotobiomodulation with blue light

    The BL will be applied to the entire DS for 60 seconds, with one session per week, for a total of 3-4 weeks depending on the healing process.

06

What researchers measure

Primary outcomes

  1. Donor Site Healing Time

    To compare the healing times of skin Donor Site treated with Standard of Care (SoC) in combination with Blue Light therapy compared to those treated with SoC.

    Time frame: From enrollment to the end of treatment at 4-5 weeks

Secondary outcomes

  1. Wound Bed Score (WBS)

    Compare skin Donor Site treated with SoC + Blue Light with those treated with SoC only, in relation to the characteristics of the wound bed, assessed using the Wound Bed Score (WBS) Modified scale. The scale ranges from 0 to 20, where higher scores indicate better wound bed conditions and improved healing potential.

    Time frame: From enrollment to the end of treatment at 4-5 weeks

  2. Numeric Pain Rating Scale (NRS)

    Assess and compare the intensity of pain perceived by the patient during the healing period, using the Numeric Rating Scale (NRS), between areas treated with and without Blue Light therapy. The scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable; therefore, higher scores indicate worse pain.

    Time frame: From enrollment to the end of treatment at 4-5 weeks

  3. Signs of Infection

    Assess the presence of signs of infection in the Donor Site by performing skin swabs on areas treated and not treated with Blue Light

    Time frame: From enrollment to the end of treatment at 4-5 weeks

  4. Local Adverse Reactions

    Monitor the appearance of any local adverse reactions (e.g. redness, burning, heat sensation, skin irritation, itching) in Donor Site undergoing experimental treatment with Blue Light.

    Time frame: From enrollment to the end of treatment at 4-5 weeks

  5. Vancouver Scar Scale (VSS)

    Compare the quality of scar outcomes at 1 and 3 months between the donor sites treated with SoC and those treated with SoC + Blue Light, using the Vancouver Scar Scale (VSS). The scale ranges from 0 to 13, where higher scores indicate more severe scar characteristics and worse scar quality.

    Time frame: 1 and 3 months after healing

07

Study locations

1 of 1 sites recruiting
  • U.O. Centro Grandi Ustionati - Osp. Maurizio Bufalini
    Cesena, Forlì-Cesena 47521, Italy
    Recruiting
08

References and documents

Publications

  • Purpura V. Blue Led Light in Burns: A New Treatment's Modality. J Clin Investig Dermatol [Internet]. 2021 [cited 2026 Jan 26];9(2). Available from: https://www.avensonline.org/fulltextarticles/JCID-2373-1044-09-0072.html
  • Zhang D, Leong ASW, McMullin G. Blue light therapy in the management of chronic wounds: a narrative review of its physiological basis and clinical evidence. Wounds. 2023 May;35(5):91-98. doi: 10.25270/wnds/22097. PubMed 37163654 ↗
  • Ricci E, Pittarello M. Blue light photobiomodulation for reactivation of healing in wounds not responding to standard therapy. J Wound Care. 2023 Nov 2;32(11):695-703. doi: 10.12968/jowc.2023.32.11.695. PubMed 37907354 ↗
  • Fraccalvieri M, Amadeo G, Bortolotti P, Ciliberti M, Garrubba A, Mosti G, Bianco S, Mangia A, Massa M, Hartwig V, Salvo P, Ricci EB. Effectiveness of Blue light photobiomodulation therapy in the treatment of chronic wounds. Results of the Blue Light for Ulcer Reduction (B.L.U.R.) Study. Ital J Dermatol Venerol. 2022 Apr;157(2):187-194. doi: 10.23736/S2784-8671.21.07067-5. Epub 2021 Sep 9. PubMed 34498454 ↗
  • Dini V, Papadia F, Francesco FD, Salvo P, Paolicchi A, Janowska A, Chiricozzi A, Oranges T. Potential correlation of wound bed score and biomarkers in chronic lower leg wounds: an exploratory study. J Wound Care. 2017 Sep 1;26(Sup9):S9-S17. doi: 10.12968/jowc.2017.26.Sup9.S9. PubMed 28880755 ↗
  • Wiechula R. The use of moist wound-healing dressings in the management of split-thickness skin graft donor sites: a systematic review. Int J Nurs Pract. 2003 Apr;9(2):S9-17. doi: 10.1046/j.1322-7114.2003.00417.x. PubMed 12694482 ↗
  • Kolimi P, Narala S, Nyavanandi D, Youssef AAA, Dudhipala N. Innovative Treatment Strategies to Accelerate Wound Healing: Trajectory and Recent Advancements. Cells. 2022 Aug 6;11(15):2439. doi: 10.3390/cells11152439. PubMed 35954282 ↗
  • Sullivan T, Smith J, Kermode J, McIver E, Courtemanche DJ. Rating the burn scar. J Burn Care Rehabil. 1990 May-Jun;11(3):256-60. doi: 10.1097/00004630-199005000-00014. PubMed 2373734 ↗
  • Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, Kvarstein G, Stubhaug A. Assessment of pain. Br J Anaesth. 2008 Jul;101(1):17-24. doi: 10.1093/bja/aen103. Epub 2008 May 16. PubMed 18487245 ↗
  • Paggi Battistino, Granara Debora, Tiziana L, Tesei Martina, Falanga Vincent. Wound Bed Score (WBS): A pilot Italian evaluation of a new modified instrument [Internet]. Unpublished; 2015 [cited 2026 Jan 27]. Available from: https://www.researchgate.net/doi/10.13140/RG.2.1.3176.4565
  • Carboni RM, Goncalves MLL, Tacla EM, Silva DFT, Bussadori SK, Fernandes KPS, Horliana ACRT, Mesquita-Ferrari RA. The effects of photobiomodulation using LED on the repair process of skin graft donor sites. Lasers Med Sci. 2022 Apr;37(3):1881-1890. doi: 10.1007/s10103-021-03447-2. Epub 2021 Oct 29. PubMed 34713365 ↗
  • Vaghardoost R, Momeni M, Kazemikhoo N, Mokmeli S, Dahmardehei M, Ansari F, Nilforoushzadeh MA, Sabr Joo P, Mey Abadi S, Naderi Gharagheshlagh S, Sassani S. Effect of low-level laser therapy on the healing process of donor site in patients with grade 3 burn ulcer after skin graft surgery (a randomized clinical trial). Lasers Med Sci. 2018 Apr;33(3):603-607. doi: 10.1007/s10103-017-2430-4. Epub 2018 Jan 24. PubMed 29368069 ↗
  • Prado TP, Zanchetta FC, Barbieri B, Aparecido C, Melo Lima MH, Araujo EP. Photobiomodulation with Blue Light on Wound Healing: A Scoping Review. Life (Basel). 2023 Feb 18;13(2):575. doi: 10.3390/life13020575. PubMed 36836932 ↗
  • de Freitas LF, Hamblin MR. Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy. IEEE J Sel Top Quantum Electron. 2016 May-Jun;22(3):7000417. doi: 10.1109/JSTQE.2016.2561201. PubMed 28070154 ↗
  • Ribeiro RVE, Martuscelli OJD. Split-thickness skin graft donor-site dressings: is it possible to establish the ideal dressing based on a literature review? Revista Brasileira de Cirurgia Plástica (RBCP) - Brazilian Journal of Plastic Sugery. 2018;33(1):119-29.
  • Serebrakian AT, Pickrell BB, Varon DE, Mohamadi A, Grinstaff MW, Rodriguez EK, Nazarian A, Halvorson EG, Sinha I. Meta-analysis and Systematic Review of Skin Graft Donor-site Dressings with Future Guidelines. Plast Reconstr Surg Glob Open. 2018 Sep 24;6(9):e1928. doi: 10.1097/GOX.0000000000001928. eCollection 2018 Sep. PubMed 30349793 ↗
  • Choong E, Jurat D, Sandeep B, Rainnie B, Manzanero S, Dowsey M, McPhail S, Choong PF, Wood F. The impact of infection on length of stay in adult burns: A scoping review. Burns. 2024 May;50(4):797-807. doi: 10.1016/j.burns.2024.01.003. Epub 2024 Jan 15. PubMed 38307765 ↗
  • Bache SE, Martin L, Malatzky D, Nessler M, Frank A, Douglas HE, Rea S, Wood FM. First do no harm: A patient-reported survey of split skin graft donor site morbidities following thin and super-thin graft harvest. Burns. 2024 Feb;50(1):41-51. doi: 10.1016/j.burns.2023.10.016. Epub 2023 Nov 2. PubMed 38008702 ↗
  • Humrich M, Goepel L, Gutknecht M, Lohrberg D, Blessmann M, Bruning G, Diener H, Dissemond J, Hartmann B, Augustin M. Health-related quality of life and patient burden in patients with split-thickness skin graft donor site wounds. Int Wound J. 2018 Apr;15(2):266-273. doi: 10.1111/iwj.12860. Epub 2017 Dec 15. PubMed 29243343 ↗
  • Guldogan CE, Kendirci M, Tikici D, Gundogdu E, Yasti AC. Clinical infection in burn patients and its consequences. Ulus Travma Acil Cerrahi Derg. 2017 Nov;23(6):466-471. doi: 10.5505/tjtes.2017.16064. PubMed 29115647 ↗
  • Bradow BP, Hallock GG, Wilcock SP. Immediate Regrafting of the Split Thickness Skin Graft Donor Site Assists Healing. Plast Reconstr Surg Glob Open. 2017 May 23;5(5):e1339. doi: 10.1097/GOX.0000000000001339. eCollection 2017 May. PubMed 28607863 ↗
  • Depoortère C, Duquennoy-Martinot V. Innesti cutanei. EMC - Tecniche Chirurgiche - Chirurgia Plastica¸ Ricostruttiva ed Estetica. 2020 Mar 1;18(1):1-11.
  • Voineskos SH, Ayeni OA, McKnight L, Thoma A. Systematic review of skin graft donor-site dressings. Plast Reconstr Surg. 2009 Jul;124(1):298-306. doi: 10.1097/PRS.0b013e3181a8072f. PubMed 19568092 ↗
  • Greenhalgh DG. Management of Burns. N Engl J Med. 2019 Jun 13;380(24):2349-2359. doi: 10.1056/NEJMra1807442. No abstract available. PubMed 31189038 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jul 2026, 10 months after the start.

Of 211 non-industry interventional studies with no phase under Burns, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 10 months is below that.

Counting every sponsor, half of 240 studies reached it within 15 months; a quarter within 6 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 6, 2026
StartActual
Sep 29, 2025
Primary completionEst.
Jul 31, 2026
CompletionEst.
Sep 28, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07453927
Lead sponsor
AUSL Romagna Rimini
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Sep 29, 2025
Primary completion
Jul 31, 2026 (estimated)
Completion
Sep 28, 2026 (estimated)
Last update
Apr 6, 2026

Study contacts

Jutta Renate Lehmann, Dr.
Contact
juttarenate.lehmann@auslromagna.it
+39 3391023866
Davide Griffa, Dr.
Contact
davide.griffa2@unibo.it
+39 3409035237

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion